LIMD2 Antibody

Code CSB-PA012950GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
LIMD2
Alternative Names
LIM domain containing 2 antibody; LIM domain-containing protein 2 antibody; Limd2 antibody; LIMD2_HUMAN antibody; MGC10986 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human LIMD2
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Acts as an activator of the protein-kinase ILK, thereby regulating cell motility.
Gene References into Functions
  1. Our data suggest that LIMD2 may play an important role in the metastatic process of papillary thyroid carcinoma PMID: 29560564
Subcellular Location
Cytoplasm. Nucleus.
Database Links

HGNC: 28142

KEGG: hsa:80774

UniGene: Hs.591166

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*